carvedilol
carvedilol: sourced relationships with 1 company · 3 clinical trials tracked · 1 FDA decision.
carvedilol evidence translation
What we can confirm
1 FDA record · 3 tracked trials
What it means
What to watch
Prepared research question
How could carvedilol → TEVA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Teva Pharmaceutical Industries Limited (TEVA) Reported 2007-09-05 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (3)
Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis: A Randomized Controlled Trial.
Primary endpoint: Proportion of patients with early variceal rebleed in 6 weeks in both the groups.
TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol (TACTIC) Trial
Primary endpoint: Rate of asymptomatic and symptomatic cardiac dysfunction
Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Primary endpoint: Time to the first identification of cardiac dysfunction
Frequently asked questions
Which companies have sourced relationships with carvedilol?
carvedilol has dated SEC/FDA relationship records for Teva Pharmaceutical Industries Limited.
How many clinical trials involve carvedilol?
BioSniper tracks 3 clinical trials involving carvedilol.
What is carvedilol's latest FDA decision?
The most recent tracked FDA decision for carvedilol is Approval, dated September 5, 2007.